Pyrilutamide (KX-826) vs RU58841: The Next Topical Anti-Androgen

Pyrilutamide and RU58841 are the two topical anti-androgens the forums argue about most, because both promise what oral finasteride cannot: a local way to block DHT at the scalp without lowering it through your whole body. The difference between them is not mechanism. It is evidence. One is being run through real human clinical trials. The other has none. Here is the honest comparison.

Same idea, two timelines

Both compounds are topical androgen receptor antagonists. They sit on the receptor inside the follicle so DHT cannot bind and trigger miniaturization, and neither is designed to lower the DHT circulating in your blood. If you already understand RU58841, start with our RU58841 complete guide, because pyrilutamide is essentially the pharmaceutical industry's attempt to do the same job with a clinical trial behind it.

Pyrilutamide (KX-826): the clinical contender

Pyrilutamide, also called KX-826, is being developed by Kintor Pharmaceutical and has gone through human clinical trials for androgenetic alopecia in both China and the United States. That alone puts it in a different category from RU58841, because there is actual trial data on humans rather than animal studies and forum reports. The results across phases have been mixed, with some trials reporting benefit and others missing their main targets, which is exactly why it is not yet a finished, approved product you can buy. It is the most legitimate topical anti-androgen in development, but it is not done.

RU58841: the underground veteran

RU58841 has the opposite profile. It was developed in the early 1990s, showed hair growth in animal models, and then never completed human development. What it has is two decades of real-world use by men who buy it as a research chemical and report results on forums. That track record is meaningful, but it is not a clinical trial, and RU58841 remains a research chemical that is not approved by the FDA for human use. You are choosing lived experience over regulated data.

Side effects and safety

Both are built on the same safety pitch: act locally on the scalp, avoid the systemic DHT suppression that drives finasteride's sexual side effects. Pyrilutamide's trials are the only place that pitch is actually being measured in humans. With RU58841 you are relying on the mechanism and user reports, with no formal safety dataset. For most men the real comparison is not pyrilutamide versus RU58841, it is whether they want a clinical-stage option that is not buyable yet, or an available compound with no trials.

Which should you care about

If you want the future, watch pyrilutamide, because an approved topical anti-androgen would be a genuine shift in the market. If you want something to run now, RU58841 is the available option, and most men pair it with minoxidil so they attack DHT and drive growth at the same time. That is the build behind our RU58841 and minoxidil serum. For the broader DHT-blocking picture, including the pill-free middle path, see topical finasteride versus RU58841.

FAQ

Is pyrilutamide better than RU58841?

Pyrilutamide has human clinical trials, which RU58841 lacks, so it has more formal evidence. But its trial results have been mixed and it is not yet an approved, widely available product, while RU58841 can be obtained now as a research chemical.

Can you buy pyrilutamide?

It is still in clinical development and not approved as a finished consumer product, so it is not reliably available the way RU58841 is.

Do pyrilutamide and RU58841 lower blood DHT?

No. Both block the androgen receptor locally so DHT cannot bind in the follicle. Neither is meant to reduce the DHT level in your bloodstream the way finasteride does.

Sources: Kintor Pharmaceutical has conducted human clinical trials of pyrilutamide (KX-826) for androgenetic alopecia in China and the United States, with mixed phase results publicly reported. RU58841 efficacy is based on early animal research and user reports, not human trials.